200 related articles for article (PubMed ID: 1624025)
21. Efficacy of a gonadotropin-releasing hormone agonist in the treatment of uterine leiomyomata: long-term follow-up.
Letterie GS; Coddington CC; Winkel CA; Shawker TH; Loriaux DL; Collins RL
Fertil Steril; 1989 Jun; 51(6):951-6. PubMed ID: 2498132
[TBL] [Abstract][Full Text] [Related]
22. Immunohistochemical detection of insulin-like growth factor type I receptor and uterine volume changes in gonadotropin-releasing hormone analog-treated uterine leiomyomas.
Di Lieto A; Iannotti F; De Falco M; Staibano S; Pollio F; Ciociola F; De Rosa G
Am J Obstet Gynecol; 2003 Mar; 188(3):702-6. PubMed ID: 12634644
[TBL] [Abstract][Full Text] [Related]
23. [Treatment of uterine leiomyoma with depot leuprorelin acetate (Enantone-Gyn monthly depot). Effect on leiomyoma volume and operability. German Leuprorelin Study Group].
Stolz W; Pfützenreuter N
Zentralbl Gynakol; 1997; 119(10):468-75. PubMed ID: 9432825
[TBL] [Abstract][Full Text] [Related]
24. Two-year results of treatment with depot leuprolide acetate for central precocious puberty.
Neely EK; Hintz RL; Parker B; Bachrach LK; Cohen P; Olney R; Wilson DM
J Pediatr; 1992 Oct; 121(4):634-40. PubMed ID: 1403402
[TBL] [Abstract][Full Text] [Related]
25. Treatment of leiomyomata uteri with D-Trp6-luteinizing hormone-releasing hormone.
Perl V; Marquez J; Schally AV; Comaru-Schally AM; Leal G; Zacharias S; Gomez-Lira C
Fertil Steril; 1987 Sep; 48(3):383-9. PubMed ID: 2957235
[TBL] [Abstract][Full Text] [Related]
26. Comparison of the suppressive capacity of different depot gonadotropin-releasing hormone analogs in women.
Filicori M; Flamigni C; Cognigni G; Dellai P; Arnone R; Falbo A; Capelli M
J Clin Endocrinol Metab; 1993 Jul; 77(1):130-3. PubMed ID: 8325935
[TBL] [Abstract][Full Text] [Related]
27. A prospective randomized study to evaluate leuprolide acetate treatment before laparoscopic myomectomy: efficacy and ultrasonographic predictors.
Zullo F; Pellicano M; De Stefano R; Zupi E; Mastrantonio P
Am J Obstet Gynecol; 1998 Jan; 178(1 Pt 1):108-12. PubMed ID: 9465812
[TBL] [Abstract][Full Text] [Related]
28. Do heavier women benefit from a higher dose of leuprolide acetate for suppression of serum estradiol?
Muneyyirci-Delale O; Weisberg GW
Int J Fertil Womens Med; 2000; 45(6):368-71. PubMed ID: 11140546
[TBL] [Abstract][Full Text] [Related]
29. Efficacy and safety of leuprolide acetate 3-month depot 11.25 milligrams or 30 milligrams for the treatment of central precocious puberty.
Lee PA; Klein K; Mauras N; Neely EK; Bloch CA; Larsen L; Mattia-Goldberg C; Chwalisz K
J Clin Endocrinol Metab; 2012 May; 97(5):1572-80. PubMed ID: 22344198
[TBL] [Abstract][Full Text] [Related]
30. Tibolone reverses the cognitive effects caused by leuprolide acetate administration, improving mood and quality of life in patients with symptomatic uterine leiomyomas.
Palomba S; Orio F; Falbo A; Oppedisano R; Tolino A; Zullo F
Fertil Steril; 2008 Jul; 90(1):165-73. PubMed ID: 18001721
[TBL] [Abstract][Full Text] [Related]
31. Fasting serum growth hormone and insulin-like growth factor-I and -II concentrations in women with leiomyomata uteri treated with leuprolide acetate or placebo.
Friedman AJ; Rein MS; Pandian MR; Barbieri RL
Fertil Steril; 1990 Feb; 53(2):250-3. PubMed ID: 2105242
[TBL] [Abstract][Full Text] [Related]
32. A randomized, controlled clinical trial comparing the effects of aromatase inhibitor (letrozole) and gonadotropin-releasing hormone agonist (triptorelin) on uterine leiomyoma volume and hormonal status.
Parsanezhad ME; Azmoon M; Alborzi S; Rajaeefard A; Zarei A; Kazerooni T; Frank V; Schmidt EH
Fertil Steril; 2010 Jan; 93(1):192-8. PubMed ID: 19135657
[TBL] [Abstract][Full Text] [Related]
33. Estriol add-back therapy in the long-acting gonadotropin-releasing hormone agonist treatment of uterine leiomyomata.
Nakayama H; Yano T; Sagara Y; Kikuchi A; Ando K; Wang Y; Watanabe M; Matsumi H; Osuga Y; Momoeda M; Taketani Y
Gynecol Endocrinol; 1999 Dec; 13(6):382-9. PubMed ID: 10685331
[TBL] [Abstract][Full Text] [Related]
34. Dose-response effect of depot leuprolide acetate on serum androgens in hirsute women.
Rittmaster RS; Arab DM; Lehman L
Fertil Steril; 1996 May; 65(5):912-5. PubMed ID: 8612847
[TBL] [Abstract][Full Text] [Related]
35. Long-term effectiveness and safety of GnRH agonist plus raloxifene administration in women with uterine leiomyomas.
Palomba S; Orio F; Russo T; Falbo A; Cascella T; Doldo P; Nappi C; Lombardi G; Mastrantonio P; Zullo F
Hum Reprod; 2004 Jun; 19(6):1308-14. PubMed ID: 15117890
[TBL] [Abstract][Full Text] [Related]
36. Effectiveness of short-term administration of tibolone plus gonadotropin-releasing hormone analogue on the surgical outcome of laparoscopic myomectomy.
Palomba S; Pellicano M; Affinito P; Di Carlo C; Zullo F; Nappi C
Fertil Steril; 2001 Feb; 75(2):429-33. PubMed ID: 11172852
[TBL] [Abstract][Full Text] [Related]
37. Use of gonadotropin-releasing hormone agonists before myomectomy.
Friedman AJ
Clin Obstet Gynecol; 1993 Sep; 36(3):650-9. PubMed ID: 8403611
[No Abstract] [Full Text] [Related]
38. Estradiol suppression and recovery during leuprolide acetate treatment in women as determined weekly by an ultrasensitive recombinant cell bioassay.
Larmore KA; Klein KO
Gynecol Endocrinol; 2000 Dec; 14(6):405-10. PubMed ID: 11228060
[TBL] [Abstract][Full Text] [Related]
39. Histopathological changes in leiomyomata treated with leuprolide acetate.
Upadhyaya NB; Doody MC; Googe PB
Fertil Steril; 1990 Nov; 54(5):811-4. PubMed ID: 2121550
[TBL] [Abstract][Full Text] [Related]
40. Effectiveness of combined GnRH analogue plus raloxifene administration in the treatment of uterine leiomyomas: a prospective, randomized, single-blind, placebo-controlled clinical trial.
Palomba S; Russo T; Orio F; Tauchmanovà L; Zupi E; Panici PL; Nappi C; Colao A; Lombardi G; Zullo F
Hum Reprod; 2002 Dec; 17(12):3213-9. PubMed ID: 12456626
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
